GLP1R and pancreas disorder: DPP-4 inhibitors and GLP-1 receptor agonists have been associated with adverse outcomes, including pancreatic disorders, although some of these findings are controversial (Butler et al., 2013; Devaraj & Maitra, 2014; Nauck, 2013).